Global Male Infertility Market - 2025-2033

Male Infertility Market Size

Male Infertility Market Size reached US$ 4.33 Billion in 2024 and is expected to reach US$ 6.62 Billion by 2033, growing at a CAGR of 4.9% during the forecast period 2025-2033.

Male Infertility Market The global male infertility market is a specialized segment within the broader fertility treatment landscape, focused on diagnosing, managing, and treating male reproductive disorders. Male infertility, defined as the inability to impregnate a fertile female partner after 12 months of unprotected intercourse, contributes to approximately 40–50% of all infertility cases globally. The market encompasses a wide range of diagnostics, therapeutic interventions, surgical treatments, and assisted reproductive technologies.

Male Infertility Market Dynamics: Drivers & Restraints

The rising prevalence of male infertility is significantly driving the male infertility market growth

According to the World Health Organization, 1 in 6 couples globally face infertility issues, and male factors contribute to around 40–50% of these cases. A growing number of men are experiencing conditions such as low sperm count, poor motility, abnormal morphology, and erectile dysfunction, all of which are directly tied to infertility. Modern lifestyle choices such as smoking, alcohol consumption, obesity, poor diet, high stress levels, and prolonged exposure to heat or radiation (e.g., from laptops, saunas, or mobile devices) have been scientifically linked to reduced male fertility.

Men are increasingly choosing to have children later in life, which correlates with a natural decline in testosterone levels and sperm quality. This trend is driving more men toward early screening, diagnostics, and fertility preservation, boosting the market for related services. As infertility becomes less stigmatized, more men are undergoing medical evaluations and fertility testing, leading to increased utilization of diagnostic tools like semen analysis, hormonal tests, and genetic screenings.

The high cost of the treatment is hampering the male infertility market

Fertility can be achieved artificially by procedures like In Vitro Fertilization (IVF), which is a common fertility treatment that involves implantation of the fertilized egg into the uterus of a female. The treatment is rather expensive, and the success rate is not so high. For instance, according to Forbes Health, one single cycle can range from $15,000 to $30,000 depending on the organization's expertise. Hormone treatments are not included in the treatment in most fertility clinics.

Male infertility diagnostics and treatments, especially advanced options like ICSI, IVF, hormone therapy, and surgical interventions, can be prohibitively expensive. Many individuals and couples cannot afford these treatments, especially in low- and middle-income countries, which limits market penetration. In many regions, male infertility treatments are considered non-essential or elective, and thus not covered by health insurance. This forces patients to pay out-of-pocket, making these services accessible primarily to wealthier populations.

Male Infertility Market Segment Analysis

The global male infertility market is segmented based on treatment, end-user, and region.

The Intracytoplasmic Sperm Injection (ICSI) from the treatment segment is expected to hold 55.01% of the market share in 2024 in the male infertility market

Intracytoplasmic Sperm Injection (ICSI) is often performed along with a combination of IVF. It is a highly valuable treatment for couples suffering from male-factor infertility. Key company strategies, such as developments and launches to advance the procedure, are expected to drive the market in the forthcoming period. For instance, in January 2024, an Australian Medtech company, Fertilis, released a prototype of microICSI, which aims to improve porcine blastocyst development and procedural efficiency for both porcine intracytoplasmic sperm injection and human microinjection.

The development of advanced ICSI equipment, better micromanipulation techniques, and global expansion of fertility clinics has made ICSI more widely available and clinically effective. For instance, in April 2025, the world’s first baby was born following conception with a fully automated, digitally controlled intracytoplasmic sperm injection (ICSI) system. ICSI, developed and adopted into widespread use in the 1990s and now a routine method of assisted conception, achieves fertilisation by injecting a single sperm cell into the centre of a mature egg.

Male Infertility Market Geographical Analysis

North America is expected to dominate the global male infertility market with a 43.92% share in 2024

North America, particularly the United States and Canada, boasts highly developed healthcare systems with access to cutting-edge diagnostic technologies, ART procedures (like ICSI and IVF), and fertility clinics. This facilitates early diagnosis and high treatment uptake. For instance, according to the Centers for Disease Control and Prevention, about 500 fertility clinics in the US help people who want to become parents, many offering comprehensive male infertility services, including genetic testing, hormone therapy, and microsurgical procedures.

Men in North America are more likely to seek medical attention for fertility issues due to greater public awareness, education campaigns, and reduced social stigma around male infertility. Organizations like the American Society for Reproductive Medicine (ASRM) and Resolve: The National Infertility Association have run nationwide campaigns to promote fertility awareness and encourage men to get tested. These initiatives further accelerate the market growth in North America.

For instance, in August 2024, the American Urological Association (AUA), in partnership with the American Society for Reproductive Medicine (ASRM), released the 2024 amendment to the Male Infertility Guideline. The purpose of this Guideline is to outline the appropriate evaluation and management of the male partner in an infertile couple. Recommendations proceed from obtaining an appropriate history and physical exam, as well as diagnostic testing, where indicated. Medical therapies, surgical techniques, and use of IUI and ART are covered to allow for optimal patient management. The 2024 amendment has introduced new evidence to support updated information on the evaluation and management of male infertility.

Asia-Pacific is growing at the fastest pace in the male infertility market, holding 22.91% of the market share

There is a notable increase in male infertility across Asia-Pacific, driven by factors such as pollution, lifestyle changes, delayed parenthood, and chronic diseases (like diabetes and obesity). Countries like India and Japan are witnessing a decline in sperm quality and fertility rates. Countries like India and Thailand are becoming hubs for fertility tourism due to the availability of advanced treatments at lower costs. This has fueled demand for male infertility services, including ICSI, semen analysis, and hormone therapy.

Asia-Pacific is rapidly adopting digital health tools, such as at-home male fertility kits, AI-based diagnostics, Intrauterine Insemination (IUI) services, and telehealth fertility consultations, making diagnostics more accessible to rural and urban populations alike. For instance, in March 2025, RMLIMS introduced Intrauterine Insemination (IUI) services. RMLIMS director Prof CM Singh said male infertility accounts for 40% of cases. He added that many men hesitate to undergo fertility tests and often blame women, which needs to change.

Male Infertility Market Top Companies

Top companies in the male infertility market include Aytu BioPharma, Inc., Cadila Pharmaceuticals, CinnaGen Co., Vitrolife, Halotech DNA, Merck KGaA, Spermosens AB, Zydus Healthcare Limited, Intas Pharmaceuticals Ltd., among others.

Male Infertility Market Key Developments

In April 2025, Boston-based techmed startup illumicell AI has secured $2 million in pre-seed funding to launch what they describe as the first portable “lab scanner” and real-time AI platform for fluid-based diagnostics, capable of analyzing cells and biomarkers within minutes. Their initial product is a portable sperm analysis scanner designed to transform male fertility care and create a broader infrastructure for cellular health data.

In June 2024, Ferring Pharmaceuticals, in partnership with Posterity Health, launched a new Male Fertility program on Ferring’s Fertility Out Loud platform that empowers men to take the initiative to understand their fertility status. This new offering features a confidential, online assessment that provides their personal reproductive health insights after completion of a questionnaire, as well as educational resources developed by Fellowship-trained Reproductive Urologists.

The global male infertility market report delivers a detailed analysis with 50 key tables, more than 47 visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.